Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 36

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 36
---
319,132 shares of Common Stock issuable upon exercise of the warrants, issued pursuant to the Securities Purchase Agreement, having a current exercise price of $36.40 per share, subject to adjustment as described in the warrants; |

| (iv). | 914,823 shares of Common Stock issuable upon conversion of the senior convertible notes, issued pursuant to the Securities Purchase Agreement, having a current conversion price of $36.40 per share, subject to adjustment as described in the senior convertible notes; and |

| (v). | 1,774,343 shares of Common Stock issuable upon exercise of the warrants, issued in the December RDO, consisting of (a) 1,642,871 shares having an exercise price of $22.72 per share and (b) 131,472 shares having an exercise price of $25.81 per share, in each case subject to adjustment as described in the applicable warrants. |

The above-referenced (a) warrants to purchase Common Stock are collectively referred to herein as the “2024 Warrants” and (b) senior convertible notes are collectively referred to herein as the “October 2024 Notes” and together with the 2024 Warrants, the “2024 Securities”.

| Shares of Common Stock outstanding prior to exercise or conversion (as applicable) of the 2024 Securities(1) | 6,951,671 shares of Common Stock (as of March 31, 2025). |

20

| Shares of Common Stock outstanding assuming exercise or conversion (as applicable) of all of the 2024 Securities | 10,544,959 shares of Common Stock (based on total shares outstanding as of March 31, 2025). |

| Use of proceeds | We intend to use the net proceeds from the exercise of the 2024 Warrants for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. We estimate that the gross proceeds to us from the exercise of the 2024 Warrants will be approximately $77.8 million, to the extent the exercise prices therefor are paid in cash. See “Use of Proceeds” elsewhere in this prospectus. |

Resale of Common Stock

| Shares of Common Stock offered by the Selling Securityholder | Up to 3,250,